Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc.AUPH · Entity 4463 | Chief Financial Officer | February 27, 2026 | March 03, 2026 |
| Avalo Therapeutics, Inc.AVTX · Entity 4936 | Director | March 31, 2022 | April 04, 2022 |
| LB PHARMACEUTICALS INCLBRX · Entity 4678 | Chief Financial Officer | October 09, 2026 | October 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aurinia Pharmaceuticals Inc.
Report date February 27, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 576,421 |
Ending reported balance
After 2026-03-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-27 · Grant · Acquired 57,229 · Balance 613,932 F1: Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement. Row 2 · 2026-03-02 · Tax withholding · Disposed 37,511 · Balance 576,421 F2: Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.97 · Expires 2036-02-27 | Direct | 95,700 |
Reported balance
After 2026-02-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-27 · Grant · Acquired 95,700 · Balance 95,700 F3: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement.
F2: Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units.
F3: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter.
Avalo Therapeutics, Inc.
Report date March 31, 2022 · Filed April 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.72 · Expires 2032-03-31 | Direct | 20,239 |
Reported balance
After 2022-03-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-31 · Grant · Acquired 20,239 · Balance 20,239 F1: 100% of the stock option will immediately vest on the date that it is granted. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the stock option will immediately vest on the date that it is granted.
LB PHARMACEUTICALS INC
Report date October 09, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Emplopyee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.22 · Expires 2036-10-08 | Direct | 200,000 |
Reported balance
After 2026-10-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-09 · Grant · Acquired 200,000 · Balance 200,000 F1: One fourth (1/4th) of the shares subject to the option award shall vest on September 2, 2027, and the remaining shares subject to the option award shall vest over the following three years on a monthly basis on the last day of the month commencing on September 30, 2027, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One fourth (1/4th) of the shares subject to the option award shall vest on September 2, 2027, and the remaining shares subject to the option award shall vest over the following three years on a monthly basis on the last day of the month commencing on September 30, 2027, subject to the Reporting Person's continuous service through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 09, 2026 Filed Oct 13, 2026 20:10 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | GrantEmplopyee Stock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $37.22 | $0.00 |
DisclosureSEC source: 0001746372-26-000007 · form4-10132026_041004.xml · derivative · entry 1 Miller Joseph M · CIK 0001746372 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2036-10-08 F1 · derivative.exercise_date: One fourth (1/4th) of the shares subject to the option award shall vest on September 2, 2027, and the remaining shares subject to the option award shall vest over the following three years on a monthly basis on the last day of the month commencing on September 30, 2027, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:14 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Tax withholdingCommon Stock | 37,511 | $14.21 | $533,031.31 |
DisclosureSEC source: 0001600620-26-000023 · wk-form4_1772572473.xml · nonDerivative · entry 2 Miller Joseph M · CIK 0001746372 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 576,421 F2 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:14 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantEmployee Stock Option (right to buy) · Derivative | 95,700 | $0.00 Strike: $13.97 | $0.00 |
DisclosureSEC source: 0001600620-26-000023 · wk-form4_1772572473.xml · derivative · entry 3 Miller Joseph M · CIK 0001746372 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,700 Underlying: Common Stock · 95,700 shares Expires 2036-02-27 F3 · derivative.exercise_date: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:14 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantCommon Stock | 57,229 | $0.00 | $0.00 |
DisclosureSEC source: 0001600620-26-000023 · wk-form4_1772572473.xml · nonDerivative · entry 1 Miller Joseph M · CIK 0001746372 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 613,932 F1 · shares: Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement. Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 21:05 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Tax withholdingCommon Stock | 32,424 | $14.40 | $466,905.60 |
DisclosureSEC source: 0001746372-26-000002 · wk-form4_1771880754.xml · nonDerivative · entry 1 Miller Joseph M · CIK 0001746372 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 556,703 F1 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 21:11 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Tax withholdingCommon Stock | 40,161 | $15.95 | $640,567.95 |
DisclosureSEC source: 0001600620-26-000003 · wk-form4_1767647470.xml · nonDerivative · entry 2 Miller Joseph M · CIK 0001746372 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 589,127 F2 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of performance awards. F3 · balance_after: Includes common shares acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 1,721 common shares were acquired on May 30, 2025 and 1,168 common shares were acquired on November 28, 2025. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 21:11 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantCommon Stock | 49,038 | $0.00 | $0.00 |
DisclosureSEC source: 0001600620-26-000003 · wk-form4_1767647470.xml · nonDerivative · entry 1 Miller Joseph M · CIK 0001746372 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 626,399 F1 · shares: Represents the number of shares earned upon certification of performance for a performance award payable solely in common shares of the Issuer that vest in two (2) equal annual installments on December 31, 2025 and December 31, 2026. Read SEC document |
| March 04, 2025 Filed Mar 5, 2025 01:58 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 56,154 | $7.92 | $444,739.68 |
DisclosureSEC source: 0001600620-25-000020 · wk-form4_1741139883.xml · nonDerivative · entry 4 Miller Joseph M · CIK 0001746372 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 577,361 F6 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of RSUs related to the March 2, 2022 and March 2, 2023 grants. F7 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.76 to $8.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 01:58 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 61,859 | $8.00 | $494,872.00 |
DisclosureSEC source: 0001600620-25-000020 · wk-form4_1741139883.xml · nonDerivative · entry 3 Miller Joseph M · CIK 0001746372 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 633,515 F4 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) related to the February 20, 2024 grant and March 2, 2023 performance award. F5 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.79 to $8.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 01:58 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantCommon Stock | 114,711 | $0.00 | $0.00 |
DisclosureSEC source: 0001600620-25-000020 · wk-form4_1741139883.xml · nonDerivative · entry 2 Miller Joseph M · CIK 0001746372 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 695,374 F3 · shares: Represents grant of performance award payable solely in common shares of the Issuer that vest in two (2) equal annual installments on December 31, 2024 and December 31, 2025. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 01:58 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantEmployee Stock Option (right to buy) · Derivative | 124,393 | $0.00 Strike: $7.55 | $0.00 |
DisclosureSEC source: 0001600620-25-000020 · wk-form4_1741139883.xml · derivative · entry 5 Miller Joseph M · CIK 0001746372 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,393 Underlying: Common Stock · 124,393 shares Expires 2035-02-28 F8 · derivative.exercise_date: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 01:58 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantCommon Stock | 81,457 | $0.00 | $0.00 |
DisclosureSEC source: 0001600620-25-000020 · wk-form4_1741139883.xml · nonDerivative · entry 1 Miller Joseph M · CIK 0001746372 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 580,663 F1 · shares: Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement. F2 · balance_after: Includes common shares acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 1,630 common shares were acquired on May 31, 2024 and 1,648 common shares were acquired on November 29, 2024. Read SEC document |
| March 06, 2024 Filed Mar 7, 2024 21:44 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 34,811 | $5.60 | $194,941.60 |
DisclosureSEC source: 0001600620-24-000037 · wk-form4_1709847876.xml · nonDerivative · entry 1 Miller Joseph M · CIK 0001746372 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 495,928 F1 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Restricted Stock Units related to the March 2, 2022 and March 2, 2023 grants. F2 · price: The price in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.475 to $5.755, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 21:27 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantCommon Stock | 196,153 | $0.00 | $0.00 |
DisclosureSEC source: 0001600620-24-000018 · wk-form4_1708637259.xml · nonDerivative · entry 1 Miller Joseph M · CIK 0001746372 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 530,739 F1 · shares: Represents grant of Restricted Stock Units (RSUs) payable solely in common stock of the Issuer that vest in three (3) equal annual installments on the first, second and third anniversary of the grant date. F2 · balance_after: Includes shares of common stock acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 1,732 shares of common stock were acquired on May 31, 2023 and 1,742 shares of common stock were acquired on November 30, 2023. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 21:29 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 11,296 | $8.94 | $100,986.24 |
DisclosureSEC source: 0001628280-23-006531 · wf-form4_167813814945028.xml · nonDerivative · entry 2 Miller Joseph M · CIK 0001746372 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,214 F5 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 21:29 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantCommon Stock | 229,421 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-006531 · wf-form4_167813814945028.xml · nonDerivative · entry 1 Miller Joseph M · CIK 0001746372 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,510 F1 · shares: Represents grant of Restricted Stock Units (RSUs) payable solely in common stock of the Issuer that vest in three (3) equal annual installments on the first, second and third anniversary of the grant date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F3 · balance_after: Includes shares of common stock acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 743 shares of common stock were acquired on May 31, 2022 and 1,656 shares of common stock were acquired on November 30, 2022. F4 · balance_after: The reporting person has reported prior awards of restricted stock units in Table II of Form 4. The total reported in Column 5 includes the 229,421 newly awarded RSUs, 104,080 RSUs previously reported in Table II, which vests in three (3) equal annual installments beginning March 2, 2022 (Prior RSUs), and 6,610 shares of common stock. On March 2, 2023, 34,693 of Prior RSUs vested and 69,387 of Prior RSUs remained unvested. Read SEC document |
| March 02, 2023 Filed Feb 22, 2024 21:17 UTC Amendment | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 11,398 | $8.78 | $100,074.44 |
DisclosureSEC source: 0001600620-24-000014 · wk-form4a_1708636621.xml · nonDerivative · entry 1 Miller Joseph M · CIK 0001746372 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 331,112 F1 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 22:06 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 20,239 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001578563-22-000011 · primary_doc.xml · derivative · entry 1 Miller Joseph M · CIK 0001746372 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,239 Underlying: Common Stock · 20,239 shares Expires 2032-03-31 F1 · shares: 100% of the stock option will immediately vest on the date that it is granted. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:12 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantStock Option (right to buy) · Derivative | 178,063 | $0.00 Strike: $12.01 | $0.00 |
DisclosureSEC source: 0001628280-22-005127 · wf-form4_164642831364007.xml · derivative · entry 4 Miller Joseph M · CIK 0001746372 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,063 Underlying: Common Stock · 178,063 shares Expires 2032-03-02 F5 · derivative.exercise_date: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:12 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantRestricted Stock Unit · Derivative | 104,080 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-005127 · wf-form4_164642831364007.xml · derivative · entry 3 Miller Joseph M · CIK 0001746372 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,080 Underlying: Common Shares · 104,080 shares Expires not disclosed F4 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. F4 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. F4 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:12 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 3,060 | $12.01 | $36,750.60 |
DisclosureSEC source: 0001628280-22-005127 · wf-form4_164642831364007.xml · nonDerivative · entry 2 Miller Joseph M · CIK 0001746372 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,610 F3 · shares: Represents the number of shares sold to cover tax withholding obligations in connection with the vesting of Performance Awards. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:12 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantCommon Stock | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-005127 · wf-form4_164642831364007.xml · nonDerivative · entry 1 Miller Joseph M · CIK 0001746372 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,670 F1 · shares: On March 18, 2021, the Reporting Person was granted stock based performance awards ("Performance Awards") which vests when specific performance metrics are met based on the results for the year ended December 31, 2021. It was determined that as of March 2, 2022, the Reporting Person partially met the performance criteria and received shares of common stock for no consideration. F2 · balance_after: Includes 170 shares acquired by the Reporting Person under the Issuer's 2021 Employee Share Purchase Plan on December 1, 2021. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 21:25 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 8,920 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001062993-22-000244 · form4.xml · derivative · entry 1 Miller Joseph M · CIK 0001746372 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,920 Underlying: Common Stock · 8,920 shares Expires 2031-12-31 F1 · shares: 100% of this stock option will immediately vest on the date that it is granted. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 20:42 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 6,939 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001878894-21-000009 · edgar.xml · derivative · entry 1 Miller Joseph M · CIK 0001746372 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,939 Underlying: Common Stock · 6,939 shares Expires 2031-09-30 F1 · shares: 100% of this stock option will immediately vest on the date that it is granted. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 20:11 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 4,620 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0001192482-21-000603 · edgar.xml · derivative · entry 1 Miller Joseph M · CIK 0001746372 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,620 Underlying: Common Stock · 4,620 shares Expires 2031-06-30 F1 · shares: 100% of this stock option will immediately vest on the date that it is granted. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:31 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $3.56 | $0.00 |
DisclosureSEC source: 0001192482-21-000520 · edgar.xml · derivative · entry 1 Miller Joseph M · CIK 0001746372 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-06-15 F1 · shares: This stock option will be fully vested and exercisable on June 15, 2022, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| May 11, 2021 Filed May 11, 2021 20:53 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | PurchaseCommon Stock | 1,000 | $9.74 | $9,740.00 |
DisclosureSEC source: 0001628280-21-009835 · wf-form4_162076642191509.xml · nonDerivative · entry 1 Miller Joseph M · CIK 0001746372 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 20:35 UTC Amendment | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 5,564 | $0.00 Strike: $3.02 | $0.00 |
DisclosureSEC source: 0001653222-21-000002 · edgar.xml · derivative · entry 1 Miller Joseph M · CIK 0001746372 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,564 Underlying: Common Stock · 5,564 shares Expires 2031-03-31 F1 · shares: 100% of this stock option will immediately vest on the date that it is granted. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 21:24 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 5,472 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001192482-21-000038 · edgar.xml · derivative · entry 1 Miller Joseph M · CIK 0001746372 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,472 Underlying: Common Stock · 5,472 shares Expires 2030-12-31 F1 · shares: 100% of this stock option will immediately vest on the date that it is granted. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 20:37 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 6,374 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0001192482-20-000755 · edgar.xml · derivative · entry 1 Miller Joseph M · CIK 0001746372 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,374 Underlying: Common Stock · 6,374 shares Expires 2030-09-30 F1 · shares: 100% of this stock option will immediately vest on the date that it is granted. Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 21:46 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 4,005 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001192482-20-000593 · edgar.xml · derivative · entry 1 Miller Joseph M · CIK 0001746372 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,005 Underlying: Common Stock · 4,005 shares Expires 2030-06-30 F1 · shares: 100% of this stock option will immediately vest on the date that it is granted. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 20:08 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.51 | $0.00 |
DisclosureSEC source: 0001192482-20-000542 · edgar.xml · derivative · entry 1 Miller Joseph M · CIK 0001746372 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-06-18 F1 · shares: This stock option will be fully vested and exercisable on June 18, 2021, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 08, 2020 Filed Jun 12, 2020 00:39 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | Tax withholdingCommon Stock | 4,472 | $3.22 | $14,399.84 |
DisclosureSEC source: 0001192482-20-000479 · edgar.xml · nonDerivative · entry 1 Miller Joseph M · CIK 0001746372 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,582 F1 · shares: Represents shares forfeited to the Issuer in connection with the satisfaction of tax liabilities incurred upon the vesting of restricted stock granted July 12, 2018. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 22:30 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 375,000 | $0.00 Strike: $2.57 | $0.00 |
DisclosureSEC source: 0001578563-20-000015 · primary_doc.xml · derivative · entry 2 Miller Joseph M · CIK 0001746372 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,000 Underlying: Common Stock · 375,000 shares Expires 2030-04-09 F2 · derivative.exercise_date: One-fourth of the shares subject to the stock option will vest on the first anniversary of the date of grant, and the remaining three-fourths of the shares subject to the stock option will vest in equal monthly installments over the following 36 months. Read SEC document |
| December 10, 2019 Filed Dec 11, 2019 21:41 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | PurchaseCommon Stock | 2,598 | $2.85 | $7,397.81 |
DisclosureSEC source: 0001578563-19-000039 · primary_doc.xml · nonDerivative · entry 1 Miller Joseph M · CIK 0001746372 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,777 F1 · shares: These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan. Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 00:47 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | PurchaseCommon Stock | 1,179 | $2.85 | $3,357.20 |
DisclosureSEC source: 0001578563-19-000022 · primary_doc.xml · nonDerivative · entry 1 Miller Joseph M · CIK 0001746372 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,179 F1 · shares: These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan. Read SEC document |
| June 07, 2019 Filed Apr 13, 2020 22:30 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | Tax withholdingCommon Stock | 3,723 | $4.85 | $18,056.55 |
DisclosureSEC source: 0001578563-20-000015 · primary_doc.xml · nonDerivative · entry 1 Miller Joseph M · CIK 0001746372 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,054 F1 · shares: Represents shares forfeited to the Issuer in connection with the satisfaction of tax liabilities incurred upon the vesting of restricted stock granted July 12, 2018. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 23:16 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $6.22 | $0.00 |
DisclosureSEC source: 0001578563-19-000011 · primary_doc.xml · derivative · entry 2 Miller Joseph M · CIK 0001746372 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2029-04-01 F1 · derivative.exercise_date: One fourth of the shares subject to the stock option will vest on the first anniversary of the date of grant, and the remaining three-fourths of the shares subject to the stock option will vest in equal monthly installments over the following 36 months. Read SEC document |
| July 12, 2018 Filed Jul 16, 2018 21:12 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 105,000 | $0.00 Strike: $4.50 | $0.00 |
DisclosureSEC source: 0001746282-18-000004 · primary_doc.xml · derivative · entry 2 Miller Joseph M · CIK 0001746372 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2028-07-11 F2 · derivative.exercise_date: The stock options will vest 25% on July 12, 2019, and the remaining 75% of the shares subject to the stock option shall vest in 36 equal monthly installments beginning on August 12, 2019, provided the Reporting Person is then an officer of the Issuer on each such vesting date. Read SEC document |
| July 12, 2018 Filed Jul 16, 2018 21:12 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001746282-18-000004 · primary_doc.xml · nonDerivative · entry 1 Miller Joseph M · CIK 0001746372 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on July 12, 2019, provided the Reporting Person is then an officer of the Issuer on each such vesting date. Read SEC document |
| July 12, 2018 Filed Apr 17, 2020 20:22 UTC Amendment | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-20-000018 · primary_doc.xml · nonDerivative · entry 1 Miller Joseph M · CIK 0001746372 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 8, 2019, provided the Reporting Person is then an officer of the Issuer on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.